Introduction
============

Despite improvements in malaria control over the past decade, malaria caused an estimated 405 000 deaths worldwide in 2018.[@R1] In 2010, World Health Organization (WHO) treatment guidelines established that all cases of suspected malaria should be confirmed by microscopy or an antigen-detecting rapid diagnostic test before treatment.[@R2] Malaria rapid diagnostic tests contain one or a combination of antibodies that recognize specific plasmodial antigens. These antigens include histidine-rich protein 2 (HRP2) which is specific to *P. falciparum*, and genus- and species-specific lactate dehydrogenase or aldolase, which are produced by all four major human-infecting *Plasmodium* species.[@R3] The number of rapid diagnostic tests procured has increased significantly, from 10 million in 2002 to 412 million in 2018.[@R1] The great majority of these tests detect an HRP2 target, alone or with another antigen, with 15 of 16 (94%) WHO-prequalified malaria tests targeting HRP2 for *P. falciparum* detection.[@R4]

Rapid diagnostic tests targeting HRP2 came to dominate the market because they are generally more sensitive than other assays and tend to be more heat stable.[@R5]^,^[@R6] The presence of repetitive epitopes in HRP2 provides numerous antibody binding sites and enables the detection of low levels of protein. The monoclonal antibodies used in HRP2-detecting tests often cross-react with HRP3, encoded by the *pfhrp3* gene,[@R7]^,^[@R8] particularly at parasite counts above 1000 per µL of blood.[@R9] HRP3 is a structural homologue of HRP2 that shares similar amino-acid repeats.[@R8]^,^[@R10]

Deletions in the *pfhrp2* and/or *pfhrp3* (*pfhrp2/3*) genes as a cause of false-negative rapid diagnostic tests was first recognized in 2010 in the Peruvian Amazon basin.[@R11] Molecular testing by polymerase chain reaction (PCR) confirmed *P. falciparum* infection, but also that *pfhrp2* and *pfhrp3* genes were deleted in 41% (61 samples) and 70% (103 samples) of these 148 samples, respectively.[@R11] Additional analyses have confirmed a significant increase in the frequency of samples showing *pfhrp2/3* deletions in the same area.[@R12]^,^[@R13] More recently, malaria parasites with *pfhrp2/3* gene deletions have been documented in other parts of the world including East,[@R9]^,^[@R14] Central,[@R15] West[@R16] and Southern Africa,[@R17] Asia[@R18] and the Middle East.[@R19] Most concerning was a study in Eritrea that reported samples from 62% (31/50) of microscopy-confirmed *P. falciparum* patients testing negative for *pfhrp2*.[@R20] Collectively, these reports suggest a global threat to the continued use of HRP2-based rapid diagnostic tests.

In 2014, recommendations on investigating and accurate reporting of *pfhrp2/3* gene deletions were published.[@R21] Additional criteria have been proposed in more recent studies, including parasite quantification by microscopy or quantitative PCR to rule out false-negative *pfhrp2* detection in samples below the limit of detection of the *pfhrp2* assay,[@R9] and analysis of *pfhrp3*.[@R22] However, we have found no assessments of the uptake of these recommendations.

There are increasing numbers of reports documenting the threat of mutant parasite genes for malaria case management. However, due to different study designs and laboratory methods it is difficult to compare findings across studies and accurately understand this threat. We aimed to compile all published studies on the prevalence of *pfhrp2/3* gene deletions and assess the quality of methods and reporting. We used our findings to paint a global picture of the current status of *pfhrp2/3* deletions to guide decisions on the locations and methods of future surveys.

Methods
=======

Search strategy and data extraction
-----------------------------------

We carried out a systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement.[@R23] We made a search of the online databases of PubMed®, Scopus, LILACS (Literatura Latino-Americana e do Caribe em Ciências da Saúde), WHO Global Index Medicus and the Web of Science for articles published in any language between 1 January 2010 and 20 August 2019. We used the search terms "\[histidine\* OR hrp\* OR pfhrp\*\] AND \[deletion\* OR variation OR diversity OR lack\] AND \[malaria OR falciparum\]" to identify articles reporting molecular analysis of *P. falciparum* parasite samples for *pfhrp2/3* deletions. Additional articles were identified through manual searches. Further information about the search criteria are provided in [Table 1](#T1){ref-type="table"}. Two investigators screened the titles and abstracts of all eligible articles and extracted the following information from the full text: country, study sites, study design, year(s) of data collection, patient symptom status, age range, number of *P. falciparum*-positive patients, type of blood sample, which samples underwent molecular analysis, number of samples with *pfhrp2*/*3* deletions, laboratory methods (seven items; [Box 1](#B1){ref-type="boxed-text"}) and analysis of flanking genes. Discrepancies in the data were double-checked.

###### Inclusion and exclusion criteria for selection of studies in the systematic review of *Plasmodium falciparum pfhrp2/3* gene deletions

  Characteristic                                                     Included                                                                                              Excluded
  ------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------
  Study population                                                   All ages and populations                                                                              None
  Study outcome                                                      Percentage of samples testing negative for *pfhrp2* gene, with or without analysis of *pfhrp3* gene   Studies which analysed variation in *pfhrp2* genetic sequence only
  Method of confirmation of *pfhrp2* and/or *pfhrp3* gene deletion   Molecular analysis of *pfhrp2/3* gene deletions                                                       Suspected deletions based on rapid diagnostic testing, microscopy or serological testing only
  Study design                                                       All, including case studies, cross-sectional or convenience studies                                   None
  Type of paper                                                      Published articles of an original study                                                               Review articles, doctoral theses, abstracts with no corresponding published article
  Patient status                                                     Symptomatic suspected malaria patients or asymptomatic people                                         None
  Area of data collection                                            All countries and regions                                                                             None
  Date of study publication                                          1 January 2010 to 20 August 2019                                                                      Prior to 1 January 2010

###### Assessment of study quality in the systematic review of *Plasmodium falciparum pfhrp2/3* gene deletions

We assessed a total of seven criteria for quality of laboratory methods, five based on recommendations from previous reasearch[@R21] and two additional criteria.[@R9]^,^[@R22] The number and percentage of studies complying with each quality criterion were as follows (*n* = 55 studies):

i.  Quality-assured microscopy: 45 studies (82%).

ii. *Plasmodium falciparum* species confirmation by PCR test: 55 studies (100%).

iii. Detection of two other single-copy genes: 21 studies (38%).

iv. HRP2 detection by serological analysis or using a second brand of WHO-prequalified HRP2-detecting rapid diagnostic test: 13 studies (24%).

v.  Detection of *pfhrp3* gene by PCR test: 46 studies (84%).

vi. Use of WHO-prequalified rapid diagnostic test: 27 studies (49%).

vii. Parasite density quantification^:^ 36 studies (66%).

We awarded one point per criterion satisfied and assigned a total quality score for each study (from 1 to 7), as follows:

Score 1: 0 studies (0%); Score 2: 6 studies (11%); Score 3: 5 studies (9%); Score 4: 16 studies (30%); Score 5: 15 studies (27%); Score 6: 10 studies (18%); Score 7: 3 studies (6%).

HRP2: histidine-rich protein 2; PCR: polymerase chain reaction; WHO: World Health Organization.

Prevalence estimates
--------------------

To maximize consistency in calculating prevalence across studies, we used the total number of *P. falciparum* samples testing positive by microscopy and confirmed *P. falciparum*-positive by species-specific PCR as the denominator. We did this regardless of whether all or only a subset of patient samples were tested for *pfhrp2/3* deletion by molecular analysis or whether it was the denominator reported in the original publication. If microscopy was not performed, we used the number of samples based on a different diagnostic method or PCR alone. We did not make prevalence estimates from case reports. All prevalence estimates in this review were therefore derived using a standardized denominator and not necessarily the same prevalence as reported in the original article.

Where researchers collected samples from multiple countries, or used different sampling methods or time frames, we separated the results by country or sample collection group to present prevalence data as separate studies. We presented compiled results for studies which collected samples at one point in time from multiple sites with the same sampling design. When we combined data from different studies by country, we weighted the percentage of samples with *pfhrp2* gene deletions to account for differing sample sizes. We used the middle year of the data collection period for studies spanning multiple years.

Assessment of study quality and bias
------------------------------------

We assigned a total quality score from 1 to 7 to each study, based on fulfilment of seven criteria for quality of laboratory methods ([Box 1](#B1){ref-type="boxed-text"}).

We assessed study bias as a score from 1 (lowest bias) to 4 (highest bias). The values show the potential bias of the derived prevalence estimate from the true prevalence in the population, depending on the sample population (symptomatic, asymptomatic, mixed or unrepresentative) and samples tested for *pfhpr2/3* genes (all, discordant only or another subset). Studies which analysed all samples have a lower bias score than those which only analysed discordant or a subset of samples, while studies which included both symptomatic and asymptomatic samples have a lower study bias than those which only analysed samples from symptomatic people or an unrepresentative sample.

Results
=======

After screening 115 articles, we included 38 articles in the review ([Fig. 1](#F1){ref-type="fig"}).[@R11]^--^[@R20]^,^[@R24]^--^[@R50] Within the articles we identified 55 distinct studies conducted in 32 countries and one territory in the regions of Africa, Americas, South-East Asia and Eastern Mediterranean ([Table 2](#T2){ref-type="table"}; available at: <http://www.who.int/bulletin/volumes/98/8/20-250621>).

![Flowchart of the literature search in the systematic review of *Plasmodium falciparum pfhrp2/3* gene deletions](BLT.20.250621-F1){#F1}

###### Studies reporting *pfhrp2 and pfhrp3* gene deletions and derived prevalence estimates by region in the systematic review of *Plasmodium falciparum pfhrp2/3* gene deletions

  Region and study                    Country or territory                 Year of data collection   Study sites                                                                                                                                                                                                                                                                       Study design                                                                    Sample population^a^   Samples tested^b^   Total no. of *P. falciparum* positive patients^c^   No. (%) of samples with gene deletions   Range of *pfhrp2* deletion prevalence across study sites   Quality score   Study bias score       
  ----------------------------------- ------------------------------------ ------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ---------------------- ------------------- --------------------------------------------------- ---------------------------------------- ---------------------------------------------------------- --------------- ------------------ --- ---
  **Africa**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Koita et al., 2012[@R41]            Mali                                 1996                      Sirakoro, Bancoumana, Doneguebougou, Bamako                                                                                                                                                                                                                                       Cross-sectional                                                                 Mixed                  Discordant          480                                                 10^d^ (2)                                NA                                                         NA              NA                 3   3
  Ramutton et al., 2012[@R35]         Democratic Republic of the Congo     2005--2010                Kinshasa                                                                                                                                                                                                                                                                          Health facility (antimalarial drug trial)                                       Unrepresentative       Subsample           6^e^                                                0 (0)                                    0 (0)                                                      0 (0)           NA                 5   2
  Ramutton et al., 2012[@R35]         Gambia                               2005--2010                Banjul                                                                                                                                                                                                                                                                            Health facility (Antimalarial drug trial)                                       Unrepresentative       Subsample           2^e^                                                0 (0)                                    0 (0)                                                      0 (0)           NA                 5   2
  Ramutton et al., 2012[@R35]         Kenya                                2005--2010                Kilifi                                                                                                                                                                                                                                                                            Health facility (antimalarial drug trial)                                       Unrepresentative       Subsample           12^e^                                               0 (0)                                    0 (0)                                                      0 (0)           NA                 5   2
  Ramutton et al., 2012[@R35]         Mozambique                           2005--2010                Beira                                                                                                                                                                                                                                                                             Health facility (antimalarial drug trial)                                       Unrepresentative       Subsample           19^e^                                               0 (0)                                    0 (0)                                                      0 (0)           NA                 5   2
  Ramutton et al., 2012[@R35]         Rwanda                               2005--2010                Kigali, Nyanza                                                                                                                                                                                                                                                                    Health facility (antimalarial drug trial)                                       Unrepresentative       Subsample           15^e^                                               0 (0)                                    0 (0)                                                      0 (0)           NA                 5   2
  Ramutton et al., 2012[@R35]         United Republic of Tanzania          2005--2010                Teule, Korogwe                                                                                                                                                                                                                                                                    Health facility (antimalarial drug trial)                                       Unrepresentative       Subsample           18^e^                                               0 (0)                                    0 (0)                                                      0 (0)           NA                 5   2
  Ramutton et al., 2012[@R35]         Uganda                               2005--2010                Mbarare                                                                                                                                                                                                                                                                           Health facility (antimalarial drug trial)                                       Unrepresentative       Subsample           5^e^                                                0 (0)                                    0 (0)                                                      0 (0)           NA                 5   2
  Wurtz et al., 2013[@R43]            Senegal                              2009--2012                Dakar                                                                                                                                                                                                                                                                             Health facility (antimalarial drug trial)                                       Symptomatic            All                 125                                                 3 (2)                                    16 (13)                                                    NA              NA                 5   2
  Laban et al., 2015[@R45]            Zambia                               2008--2012                Choma                                                                                                                                                                                                                                                                             Cross-sectional                                                                 Mixed                  All                 61                                                  NA                                       NA                                                         12^f^ (20)      NA                 4   1
  Amoah et al., 2016[@R16]            Ghana                                2015                      Abura Dunkwa, Obom                                                                                                                                                                                                                                                                Malaria screening programme                                                     Mixed                  All                 288                                                 76 (26)                                  85 (30)                                                    37 (13)         22--40             6   1
  Parr et al., 2017[@R15]             Democratic Republic of the Congo     2013--2014                Kinshasa, Kwango, Kwilu, Mai-Ndombe, Kongo Central, Equateur, Mongala, Nord-Ubangi, Sud-Ubangi, Tshuapa, Kasai, Kasai-Central, Kasai-Oriental, Lomami, Sankuru, Haut-Katanga, Haut-Lomami, Lualaba, Tanganyka, Maniema, Nord-Kivu, Bas-Uele, Haut-Uele, Ituri, Tshopo, Sud-Kivu   Cross-sectional                                                                 Mixed                  Discordant          2752^g^                                             149^h^ (5)^i^                            NA                                                         5 (\< 1)        0--22              5   3
  Beshir et al., 2017[@R9]            Kenya                                2014                      Mbita                                                                                                                                                                                                                                                                             Cross-sectional in schools (mosquito behaviour study)                           Asymptomatic           All                 131                                                 8 (6)                                    1 (1)                                                      0 (0)           NA                 6   2
  Beshir et al., 2017[@R9]            Kenya                                2007--2008                Kilifi                                                                                                                                                                                                                                                                            Health facility                                                                 Symptomatic            All                 49                                                  1 (2)                                    1 (2)                                                      0 (0)           NA                 4   2
  Gupta et al., 2017[@R17]            Mozambique                           2010--2016                Manhiça, Magude                                                                                                                                                                                                                                                                   Cross-sectional                                                                 Mixed                  Discordant          1162                                                1^j^ (\< 1)                              0 (0)                                                      0 (0)           NA                 6   3
  Kozycki et al., 2017[@R14]          Rwanda                               2014--2015                Busogo, Kiribizi, Bukara                                                                                                                                                                                                                                                          Health facility                                                                 Symptomatic            Discordant          3291                                                32^k^ (1)                                NA                                                         NA              NA                 4   4
  Menegon et al., 2017[@R36]          Eritrea                              2013--2014                Gash Barka, Debun                                                                                                                                                                                                                                                                 Unknown                                                                         Unknown                All                 144                                                 14 (10)                                  62 (43)                                                    13 (9)          9--22              4   2
  Ranadive et al., 2017[@R37]         Eswatini                             2012--2014                Lubombo                                                                                                                                                                                                                                                                           Health facility                                                                 Symptomatic            Discordant          162^c^                                              0^l^ (0)                                 1 (1)                                                      0 (0)           NA                 4   2
  Berhane et al., 2018[@R20]          Eritrea                              2016                      Northern Red Sea, Anseba, Gash Barka, Debub                                                                                                                                                                                                                                       Health facility                                                                 Symptomatic            All                 50                                                  31 (62)                                  41 (82)                                                    31 (62)         42--81             7   2
  Nderu et al., 2018[@R39]            Kenya                                2007--2016                Busia, Mbita, Nyando, Tiwi, Msambweni                                                                                                                                                                                                                                             Drug efficacy trial                                                             Symptomatic            All                 400                                                 0 (0)                                    0 (0)                                                      0 (0)           NA                 5   2
  Owusu et al., 2018[@R38]            Ghana                                2015                      Greater Accra, Eastern region                                                                                                                                                                                                                                                     Cross-sectional study among patients attending antiretroviral therapy clinics   Unrepresentative       Discordant          62                                                  6^m^(10)                                 8 (13)                                                     6 (10)          NA                 4   3
  Willie et al., 2018[@R40]           Madagascar                           2014--2015                Yurimaguas                                                                                                                                                                                                                                                                        Health facility                                                                 Symptomatic            All                 73                                                  0 (0)                                    NA                                                         NA              NA                 3   2
  Funwei et al., 2019[@R42]           Nigeria                              2013--2014                Elata Ibadan                                                                                                                                                                                                                                                                      Health facility                                                                 Symptomatic            Discordant          340                                                 11n (3)                                  4 (1)                                                      11 (3)          NA                 6   4
  Kobayashi et al., 2019[@R46]        Zambia                               2009--2011                Choma                                                                                                                                                                                                                                                                             Cross-sectional                                                                 Mixed                  Discordant          45                                                  3^o^ (7)                                 NA                                                         0 (0)           NA                 5   3
  Kobayashi et al., 2019[@R46]        Zambia                               2015--2017                Nchelenge                                                                                                                                                                                                                                                                         Cross-sectional                                                                 Mixed                  Discordant          1144                                                0^p^ (0)                                 NA                                                         0 (0)           NA                 6   3
  **Americas**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Gamboa et al., 2010[@R11]           Peru                                 2003--2007                Iquitos area, Loreto, Amazonas, Cajamarca                                                                                                                                                                                                                                         Health facility                                                                 Unknown                All                 148                                                 61 (41)                                  103 (70)                                                   31 (22)         36--100            4   2
  Gamboa et al., 2010[@R11]           Peru                                 2007                      Iquitos                                                                                                                                                                                                                                                                           Active case detection survey                                                    Symptomatic            All                 9                                                   8 (90)                                   6 (67)                                                     4 (44)          NA                 7   2
  Houzé et al., 2011[@R25]            Brazil                               2011                      Amazon region                                                                                                                                                                                                                                                                     Case study                                                                      Symptomatic            Discordant          1                                                   1^q^                                     1^q^                                                       1^q^            NA                 5   4
  Maltha et al., 2012[@R12]           Peru                                 2010--2011                Iquitos area                                                                                                                                                                                                                                                                      Health facility, active case detection                                          Symptomatic            All                 74                                                  19 (26)                                  34 (44)                                                    19 (26)         NA                 6   2
  Akinyi et al., 2013[@R13]           Peru                                 1998--2001                Loreto, Piura                                                                                                                                                                                                                                                                     Unknown                                                                         Symptomatic            All                 92^c^                                               19 (21)                                  NA                                                         NA              0--36              2   2
  Akinyi et al., 2013[@R13]           Peru                                 2003--2005                Iquitos                                                                                                                                                                                                                                                                           Unknown                                                                         Symptomatic            All                 96^c^                                               39 (41)                                  NA                                                         NA              NA                 2   2
  Trouvay et al., 2013[@R29]          French Guiana                        2009                      St Luarent du Maroni, Cayenne, St Georges de l'Oyapack, Saul, Antecume Pata                                                                                                                                                                                                       Unknown                                                                         Symptomatic            All                 140^c^                                              0 (0)                                    4 (3)                                                      0 (0)           NA                 2   2
  Trouvay et al., 2013[@R29]          French Guiana                        2010--2011                Cayenne Hospital                                                                                                                                                                                                                                                                  Health facility survey                                                          Symptomatic            All                 81                                                  0 (0)                                    6 (7)                                                      0 (0)           NA                 5   2
  Abdallah et al., 2015[@R32]         Honduras                             2008--2009                Puerto Lempira                                                                                                                                                                                                                                                                    Health facility (antimalarial drug trial)                                       Symptomatic            All                 68^c^                                               0 (0)                                    30 (44)                                                    0 (0)           NA                 2   2
  Akinyi Okoth et al., 2015[@R31]     Guyana                               2009--2011                Georgetown (Cuyuni-Mazaruni, Potaro-Siparuni)                                                                                                                                                                                                                                     Health facility survey                                                          Symptomatic            All                 97                                                  0 (0)                                    0 (0)                                                      0 (0)           NA                 3   2
  Akinyi Okoth et al., 2015[@R31]     Suriname                             2009--2011                Sipaliwini, Brokopondo                                                                                                                                                                                                                                                            Health facility survey, active case detection                                   Symptomatic            All                 78                                                  11 (14)                                  3 (4)                                                      2 (3)           0--48              3   2
  Baldeviano et al., 2015[@R33]       Peru                                 2010--2012                Tumbes                                                                                                                                                                                                                                                                            Health facility during malaria outbreak                                         Symptomatic            All                 54                                                  54 (100)                                 NA                                                         NA              NA                 2   2
  Murillo Solano et al., 2015[@R26]   Colombia                             2008--2009                Cordoba, Narino, Valle del Cauca,                                                                                                                                                                                                                                                 Unknown                                                                         Symptomatic            All                 75                                                  4 (5)                                    40 (53)                                                    4 (5)           0--33              6   2
  Murillo Solano et al., 2015[@R26]   Colombia                             1999--2007                Amazonas, Guaviare, Meta                                                                                                                                                                                                                                                          Epidemiological studies                                                         Symptomatic            All                 25                                                  14 (56)                                  12 (48)                                                    9 (36)          0--67              4   2
  Sáenz et al., 2015[@R28]            Ecuador                              2012--2013                Esmereldas                                                                                                                                                                                                                                                                        Malaria outbreak surveillance                                                   Symptomatic            All                 32                                                  1 (3)                                    1 (3)                                                      1 (3)           NA                 4   2
  Dorado et al., 2016[@R27]           Colombia                             2003--2010                Antiquia, Amazonas, Guaviare, Narino, Choco, Cauca, Valle                                                                                                                                                                                                                         Unknown                                                                         Symptomatic            All                 253                                                 15 (6)                                   106 (42)                                                   15 (6)          0--54              4   2
  Dorado et al., 2016[@R27]           Colombia                             2011--2012                Antiquia, Amazonas, Guaviare, Narino, Choco, Cauca, Valle                                                                                                                                                                                                                         Health facility survey                                                          Symptomatic            All                 112                                                 0 (0)                                    51 (42)                                                    0 (0)           NA                 6   2
  Okoth et al., 2016[@R34]            Peru                                 2013                      Cusco                                                                                                                                                                                                                                                                             Outbreak surveillance                                                           Symptomatic            All                 4                                                   4 (100)                                  4 (100)                                                    4 (100)         NA                 4   2
  Rachid Viana et al., 2017[@R24]     Bolivia (Plurinational State of)     2010--2012                Beni department                                                                                                                                                                                                                                                                   Health facility survey                                                          Symptomatic            All                 25^c^                                               1 (4)                                    17 (68)                                                    0 (0)           NA                 3   2
  Rachid Viana et al., 2017[@R24]     Brazil                               2010--2012                Acre, Para, Rondonia                                                                                                                                                                                                                                                              Health facility survey                                                          Symptomatic            All                 198                                                 27 (14)                                  71 (36)                                                    43 (23)         0--32              4   2
  Fontecha et al., 2018[@R30]         Guatemala                            2015                      Escuintla                                                                                                                                                                                                                                                                         Malaria surveillance survey                                                     Symptomatic            All                 21                                                  3 (14)                                   19 (91)                                                    3 (14)          NA                 4   2
  Fontecha et al., 2018[@R30]         Honduras                             2011--2017                Gracias a Dios, Colon, Antantida, Cortes, Islas de la Bahia                                                                                                                                                                                                                       Health facility survey for drug resistance                                      Symptomatic            All                 52                                                  13 (25)                                  50 (96)                                                    13 (25)         0--40              4   2
  Fontecha et al., 2018[@R30]         Nicaragua                            2015                      North Atlantic Autonomous Region                                                                                                                                                                                                                                                  Malaria surveillance survey                                                     Symptomatic            All                 55                                                  17 (31)                                  48 (87)                                                    11 (20)         NA                 4   2
  **South-East Asia**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Kumar et al., 2013[@R49]            India                                2010                      Chhattisgarh                                                                                                                                                                                                                                                                      Unknown                                                                         Symptomatic            All                 48^c^                                               2 (4)                                    2 (4)                                                      2 (4)           NA                 6   2
  Li et al., 2015[@R48]               China--Myanmar border, Thailand^r^   2011--2012                China, Myanmar border and Tak province, Thailand                                                                                                                                                                                                                                  Mass blood survey, unknown                                                      Unknown                All                 97                                                  4 (4)                                    3^s^ (3)                                                   3 (3)           NA                 5   2
  Bharti et al., 2016[@R18]           India                                2014                      Odisha, Chhattisgarh, Jharkhand, Madhya Pradesh, Maharashtra, Rajasthan, Gujarat, Tripura                                                                                                                                                                                         Health facility                                                                 Symptomatic            Discordant          1521                                                36^t^ (2)                                27 (2)                                                     25 (2)          0--25              6   4
  Nima et al., 2017[@R47]             Bangladesh                           2013                      Sylhet                                                                                                                                                                                                                                                                            Case study                                                                      Symptomatic            Discordant          1                                                   1^q^                                     1^q^                                                       1^q^            NA                 5   4
  Pati et al., 2018[@R50]             India                                2013--2016                Odisha                                                                                                                                                                                                                                                                            Cross-sectional                                                                 Symptomatic            Discordant          384                                                 38^u^ (10)                               24 (6)                                                     17 (4)          8--14              7   4
  **Eastern Mediterranean**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Atroosh et al., 2015[@R19]          Yemen                                2014                      Hodeidah, Al-Mahwit                                                                                                                                                                                                                                                               Active case detection                                                           Symptomatic            All                 189                                                 9 (5)                                    NA                                                         NA              NA                 4   2
  Mussa et al., 2019[@R44]            Sudan                                Unrepresentative          Omdurman                                                                                                                                                                                                                                                                          Health facility                                                                 Symptomatic            All                 26                                                  9 (35)                                   NA                                                         NA              NA                 2   2

DNA: deoxyribonucleic acid; HRP2: histidine-rich protein 2; NA: not applicable; PCR: polymerase chain reaction.

^a^ Symptomatic: only symptomatic people tested; Mixed: mix of symptomatic and asymptomatic people tested; Asymptomatic: only asymptomatic people tested; Unrepresentative: a subset of people not representative of the population were tested; Unknown: not reported.

^b^ All: all samples underwent molecular analysis; Discordant: only discordant samples tested; Subsample: another subset of samples tested.

^c^ As microscopy was not performed, we used the number of *P. falciparum* positive cases by PCR as the denominator.

^d^ Only 22 samples which were rapid diagnostic test-negative and microscopy-positive samples were analysed for *pfhrp2* deletion.

^e^ Samples testing positive by *P. falciparum*-specific lactate dehydrogenase rapid diagnostic test and confirmed by PCR. Only those samples with the lowest level of HRP2 were analysed with molecular methods.

^f^ Only the HRP-leader sequence shared by both *pfhrp2* and *pfhrp3* genes was tested, so we could not break down results by *pfhrp2* or *pfhrp3* genes.

^g^ Microscopy-positive and -negative samples were analysed. PCR-positive samples are included here.

^h^ Only 783 samples which were rapid diagnostic test-negative and PCR-positive were analysed for *pfhrp2* deletion.

^i^ Results differ from those presented in the article as we presented unweighted results.

^j^ Only 69 samples which were rapid diagnostic test-negative and microscopy-positive were analysed for *pfhrp2* deletion.

^k^ Only 138 samples which were rapid diagnostic test-negative and microscopy-positive were analysed for *pfhrp2* deletion.

^l^ Only nine samples which were rapid diagnostic test-negative and quantitative PCR-positive with a parasite counts \> 100 per μL were analysed for *pfhrp2* deletion.

^m^ Only eight samples which were rapid diagnostic test-negative and PCR positive were analysed for *pfhrp2* deletion.

^n^ Only 66 samples which were rapid diagnostic test-negative and microscopy- or PCR-positive were analysed for *pfhrp2* deletion.

^o^ Only eight samples which were rapid diagnostic test-negative and quantitative PCR-positive with *pfldh* DNA concentration \> 0.0001 ng per µL *P. falciparum* DNA were analysed for *pfhrp2* deletion.

^p^ Only 28 samples which were rapid diagnostic test-negative and microscopy-positive with *pfldh* DNA concentration \> 0.0001 ng per µL *P. falciparum* DNA were analysed for *pfhrp2* deletion.

^q^ We did not present prevalence for case studies.

^r^ Article reported collection of samples from three countries but did not present results separately, so the results have been presented here as one study.

^s^ 97 samples were tested for *pfhrp2* deletion, however only the four negative samples were analysed for *pfhrp3* deletion. We present results out of the 97 samples analysed.

^t^ Only 50 samples which were rapid diagnostic test-negative and microscopy-positive were analysed for *pfhrp2* deletion.

^u^ Only 58 samples which were rapid diagnostic test-negative and microscopy-positive were analysed for *pfhrp2* deletion.

Notes: We calculated the prevalence of gene deletions using all *Plasmodium falciparum*-positive samples as the denominators. All studies used microscopy with PCR confirmation, except where indicated. In some cases, only rapid diagnostic test-negative, microscopy-positive samples or rapid diagnostic test-negative, PCR-positive samples were analysed for *pfhrp2* gene deletion, as indicated in footnotes above. We scored study quality from 1 (lowest) to 7 (highest), as described in [Box 1](#B1){ref-type="boxed-text"}, and study bias from 1 (lowest) to 4 (highest).

Study characteristics
---------------------

The included studies showed substantial differences in study design, laboratory methods and data reporting.

### Sample populations

The number of samples tested for *pfhrp2* ranged from 1 to 783, while the denominator of *P. falciparum*-positive samples ranged from 1 to 3291 ([Table 2](#T2){ref-type="table"}). Out of the 55 studies, 36 (65%) analysed blood samples only from people with symptoms of malaria, as part of a prospective or retrospective survey including unbiased cohorts. Samples in these studies were collected from suspected malaria patients presenting to health facilities or through active case detection. Eight studies (15%) included samples from asymptomatic and symptomatic people as part of cross-sectional surveys or malaria screening programmes, while eight other studies (15%) used samples from an unrepresentative sample of participants and three studies (5%) did not specify the symptom status of the participants. One study collected samples from patients with severe malaria only, while one study collected equal numbers of samples from human immunodeficiency virus-positive and -negative children.

In 35 studies (64%) all samples underwent *pfhrp2/3* genotyping. Thirteen studies (24%) genotyped discordant samples only. Of these, nine studies analysed only microscopy-positive and HRP2-rapid diagnostic test-negative samples (of which two were case studies including only one sample), while four studies genotyped only samples which were negative by HRP2-rapid diagnostic test and positive by PCR. One article reporting seven studies only genotyped samples showing the lowest HRP2 concentrations by enzyme-linked immunosorbent assay.

### Study procedures

Only three studies (5%) fulfilled all seven criteria for quality of procedures ([Box 1](#B1){ref-type="boxed-text"}). While the number of *P. falciparum*-positive samples was based on microscopy- and PCR-positive results in 45 studies (82%), in nine studies (16%) the denominator was based on PCR results alone, and in one study (2%) it was based on *P. falciparum*-specific lactate dehydrogenase-based rapid diagnostic tests and confirmed by PCR. The presence of *P. falciparum* was confirmed most commonly by amplification of the multi-copy *18SrRNA* gene. Thirty-four studies (62%) analysed samples from dried blood spots, 13 (24%) used venous blood, seven (13%) used a combination of both and one study (2%) did not provide information on sample type. Forty-six studies (84%) conducted molecular analysis to determine *pfhrp3* deletion. One of these studies only genotyped *pfhrp3* deletions among samples found to be *pfhrp2-*negative.

Twenty-one studies (38%) did not amplify any other single-copy genes while 13 studies (24%) amplified one other and 21 studies (38%) amplified at least two other single-copy genes. To rule out negative *pfhrp2/3* PCR results being due to parasite density below the limit of detection of the assay, only samples which were positive by other single-copy genes and failed to amplify the *pfhrp2/3* gene were considered to be *pfhrp2/3*-deleted in the 21 studies which conducted this analysis. The most commonly selected genes for confirmation were *P. falciparum* merozoite surface proteins 1 and 2, and glutamate-rich protein. One study confirmed *pfhrp2* deletion by testing for *pfhrp3*. However, while parasite density was measured in 36 studies, only five studies used these results when determining if a sample was *pfhrp2/3*-negative. In three studies only samples above a chosen parasite density or deoxyribonucleic acid (DNA) concentration were tested for *pfhrp2*, while in one study all samples below 5 parasites per µL of blood were discounted and in one study samples were only included in the original study if they were above 2000 parasites per µL of blood.

Twenty-nine studies (53%) amplified both exons 1 and 2 of the *pfhrp2* gene, while 26 studies (47%) amplified only exon 2 and 28 studies (51%) amplified the flanking genes of *pfhrp2*. The studies that amplified exon 1 were not necessarily those that amplified flanking genes, with 19 studies (35%) amplifying both exon1 and flanking genes.

Prevalence estimates
--------------------

The derived prevalence of *pfhrp2* gene deletions in the 55 studies ranged from 0% to 100% ([Table 2](#T2){ref-type="table"}). Although we present the overall results by study, 14 studies were conducted over many sites and showed geographically heterogenous results. Further details about the results presented by region are provided in the data repository.[@R51]

In [Fig. 2](#F2){ref-type="fig"} we mapped the geographical distribution of the highest derived prevalence estimate of *pfhrp2* gene deletions by study for each country. The highest derived prevalence was above 50% in Colombia, Eritrea and Peru. [Fig. 3](#F3){ref-type="fig"} plots the weighted average prevalence of *pfhrp2* gene deletions for each country and the range by study sites. The weighted average prevalence ranged from 0% to 43%. Average prevalence above 20% was found in Eritrea, Ghana, Nicaragua, Peru and Sudan.

![Geographical distribution of highest prevalence estimates for *Plasmodium falciparum pfhrp2* gene deletions by study among patients tested at the country level](BLT.20.250621-F2){#F2}

![Weighted average prevalence estimates for *Plasmodium falciparum pfhrp2* gene deletions among patients tested by country](BLT.20.250621-F3){#F3}

We plotted the prevalence of *pfhrp2*/3 gene deletions by sample size (available in the data repository).[@R52] Five studies had a sample size over 1000, while 36 had sample sizes smaller than 100. All seven studies reporting greater than 50% prevalence of *pfhrp2* deletions had a sample size of fewer than 55. Scatter plots of prevalence against time are available in the data repository.[@R53]

Risk of bias
------------

[Table 2](#T2){ref-type="table"} shows the bias scores of the prevalence estimates from the true prevalence of *pfhrp2/3* gene deletions in the population. Six studies (11%) had a bias score of four while two (4%) had a bias score of one.

Discussion
==========

We found that mutant parasites have been reported from all major malaria-endemic areas, in asymptomatic and symptomatic *P. falciparum*-positive patients. However, our results also confirm that the full extent of the threat has not yet been characterized. The limited number of well conducted prevalence surveys in malaria-endemic countries indicate geographical variability in the prevalence of mutations in the *pfhrp2* and *pfhrp3* genes and do not completely illuminate the factors driving these differences.

The study has limitations. Although we included only published articles, we were aware of other abstracts and doctoral theses for which relevant data on methods were not available. For manuscripts included in the review, we contacted authors to obtain information not included in the manuscripts; this was not always possible, however, and we therefore occasionally made assumptions about the methods. Survey design and sample populations varied greatly across the included studies. Most studies were not purposely designed for investigating the prevalence of gene deletions and relied on convenience sampling or on secondary analyses of existing specimens. These shortcomings limit our ability to draw conclusions that can inform the use of rapid diagnostic testing, but rather provides guidance for future surveys.

Reconciling the different populations and sample sizes across studies is challenging. First, studies of asymptomatic and symptomatic patients require different interpretations and are difficult to integrate. Samples from asymptomatic patients may have lower parasite densities, resulting in less DNA target for amplification and potentially greater risk of falsely reporting *pfhrp2* deletions. This risk is especially high when the investigation does not include amplification of other single-copy genes or does not quantify parasite DNA. Furthermore, little is known about the effect of *pfhrp2/3* gene deletions on the virulence of malaria infection. If *pfhrp2/3* deletions are associated with less virulent infections, there could be a difference in prevalence between symptomatic and asymptomatic infections. We found numerous studies with low sample sizes which may not be representative of the true prevalence of deletions in a population or country.

Second, different selection criteria for *pfhrp2/3* genotyping (all malaria suspects or only those with discordant HRP2-based rapid diagnostic test and microscopy and/or PCR results) result in the use of different numerators and denominators for prevalence estimation across studies. Analysis limited to deletions found among discordant samples leads to a higher prevalence of gene deletions being reported. To improve consistency in calculating the prevalence of *pfhrp2-*negative mutants, we used the total number of samples with confirmed *pfhrp2* gene deletions by species-specific PCR as the numerator and the total cohort number of *P. falciparum*-positive samples by microscopy and/or PCR as the denominator. The WHO-recommended approach of testing only a subset of high-risk (discordant) samples is a more economical way of monitoring the prevalence of gene deletion and targets clinically significant deletions that cause negative test results. WHO recommends using non-exclusive HRP2-based rapid diagnostic tests when the prevalence of *pfhrp2/3* gene deletions causing false-negative test results is greater than 5%.[@R22] Most studies included in this review did not allow us to determine if the WHO threshold had been exceeded. It is well acknowledged that the WHO approach may underestimate the prevalence of *pfhrp2* deletions in the parasite population. Samples that are *pfhrp2-*negative and *pfhrp3*-positive are not likely to be flagged as high risk or discordant due to the cross-reactivity between HRP2 and HRP3 proteins on many rapid diagnostic test brands. However, this concern does not pose an immediate threat to patients.[@R54] Ideally, all *P. falciparum*-positive samples should be used as the denominator, determined either by microscopy or a good quality rapid diagnostic test for detecting *P. falciparum*-specific lactate dehydrogenase.

The study bias scores show the potential bias of the prevalence estimates from the true prevalence of *pfhrp2/3* gene deletions in the population, but not necessarily the bias of deletions causing false-negative results (which is more important for determining the effect on malaria case management). Ultimately, high-throughput screening options could become more readily available and more commonly used. If so, the true prevalence of *pfhrp2* gene deletions could be determined by molecular testing of all people with suspected malaria regardless of rapid diagnostic test or microscopy results, and those samples confirmed to have *pfhrp2* deletions used as the numerator.

Third, recent modelling suggests that the likelihood of finding *pfhrp2/3* deletions can vary during the malaria transmission season due to changes in the transmission intensity and multiplicity of infection, whereby a person can be infected with multiple *P. falciparum* strains.[@R55] Co-infection with *pfhrp2/3*-negative- and wild-type parasites can prevent detection of gene deletions using current laboratory techniques, leading to an underestimation of the prevalence of *pfhrp2/3*-negative mutants. Time of year and relation to the transmission season is rarely described in published reports. A publicly available database using prediction models could be useful to help determine the optimal time in the transmission season to conduct a gene deletion survey.[@R56]

Due to the small number of studies, differing populations and often small samples sizes of the reviewed studies, it is difficult to draw robust conclusions on the prevalence of *pfhrp2/3* gene deletions in specific areas or to perform meta-analysis from these data. The implementation of more large-scale, robust surveys would enable a better understanding of if, and at what rate, these mutations are increasing in a given area, and would allow for meta-analysis.

Identifying the prevalence of *pfhrp2/3* deletion mutations requires synthesis of several lines of evidence and study procedures that include proper performance of rapid diagnostic tests and careful genotyping methods. While most studies in this review followed some components of published criteria to classify a sample as *pfhrp2*-deleted,[@R21] only 3 (5%) of the studies followed the seven recommended criteria proposed in this review. One specific challenge for molecular analyses of *pfhrp2/3* is using the absence of amplified products as the indicator of interest, rather than the presence of amplified products. Rigorous methods and appropriate controls must be used to ensure the presence of non-degraded, amplifiable parasite DNA and the lack of amplicon contamination. Improving the accuracy of survey outcomes requires novel molecular-based technology and methods that could detect *pfhrp2/3* gene deletions more reliably and efficiently and detect *pfhrp2/3* deletions in samples with mixed infections (such as quantitative-PCR and whole genome sequencing). Not all malaria-endemic countries have the capacity to conduct molecular analysis to a high standard, and establishing such capacity is challenging and costly. In addition, the sensitivity and specificity of PCR assays can be affected by the protocol used, potentially resulting in variations in the results across laboratories following different procedures. For example, lowering the elongation temperature on *pfhrp2* assays improved the limit of detection of many previously published assays.[@R57] WHO has established a network of laboratories capable of conducting this analysis to ensure that samples from prevalence surveys can be performed quickly and procedures harmonized across laboratories.[@R22]

Just over half of the studies amplified both exon 1 and 2 of the *pfhrp2* gene, while the rest amplified only exon 2. While the chromosomal break points could theoretically be anywhere within the *pfhrp2* gene, it appeared that most samples from Eritrea and Peru have observed deletions in both exon 1 and 2 (Qin Cheng, Australian Defence Force Malaria and Infectious Disease Institute, personal communication, 2019). Therefore, whether analysis of exon 2 alone is sufficient to identify most parasites with *pfhrp2* gene deletions requires further analysis of gene deletions from other parasite populations. While not included in the recommendations for *pfhrp2/3* molecular analysis,[@R21] analysis of flanking genes can provide additional information on genetic mutations.

Despite the diversity of study approaches, there appear to be areas of high prevalence of *pfhrp2/3* mutant parasites where diagnostic testing based on HRP2 alone would be inadequate. Thus, the need for alternative rapid diagnostic tests is of urgent concern in the Amazon basin and Eritrea, where the prevalence of tests producing false-negative results among symptomatic patients has forced changes in the diagnostic strategy.[@R58] Malaria control programmes should remain vigilant for evidence suggesting the presence of *pfhrp2/3* gene deletions. Evidence of false-negative rapid diagnostic tests or confirmed *pfhrp2/3-*negative mutants in neighbouring countries should trigger careful investigation and surveillance. To improve the quality and relevance of surveys for clinical case management, WHO now provides general guidance on when to prioritize surveys for *pfhrp2/3* deletions.[@R22] WHO has also developed protocols for guiding survey design, data collection and laboratory methods to determine the prevalence of clinically-relevant *pfhrp2/3* deletions causing false-negative rapid diagnostic tests.[@R59] The guidelines aim to ensure that future investigations are implemented to high and comparable standards. Additionally, an up-to-date repository of *pfhrp2/3* deletion studies is maintained on the WHO malaria threat map.[@R60]

The specific factors that drive the evolution and spread of *pfhrp2/3* mutations are not clear, although mathematical models suggest that selective pressure by HRP2-detecting rapid diagnostic tests over the past decade is likely to have played an important role.[@R5] Low malaria transmission and high frequency of people correctly treated on the basis of diagnosis with HRP2-detecting tests have also been identified as key drivers of the selection of *pfhrp2/3*-negative mutants.[@R61] Nevertheless, the existence and rising prevalence of *pfhrp2* deletions in Peru,[@R11]^,^[@R12]^,^[@R33] where HRP2-only methods have never been widely used, along with the local prevalence of *pfhrp3* mutations, confirms that selective treatment based on test results is not the only factor driving the evolution of these parasites.

Due to the global reliance on rapid diagnostic tests for malaria diagnosis, a coordinated, multifaceted response to P. falciparum with *pfhrp2/3* gene deletions is required. This response should include representative studies of the prevalence and distribution of *pfhrp2/3* deletions, more efficient and affordable methods for screening and confirming these deletions, and efforts to standardize and ensure high-quality reporting. Follow-up surveys in areas with documented *pfhrp2/3* deletions will provide insight into the speed at which the mutant parasites are evolving in response to diagnostic pressure and other drivers. Research for the development and commercialization of rapid diagnostic tests based on new or improved non-HRP2 targets is an essential parallel area of work.
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